Powder: -20°C for 3 years | In solvent: -80°C for 1 year
FLLL32是一种姜黄素的合成类似物,是JAK2/STAT3的双重抑制剂,具有抗肿瘤癌活性。它作用于乳腺癌细胞,可抑制 IFNα 和 IL-6 诱导的 STAT3 磷酸化。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 293 | 现货 | ||
2 mg | ¥ 438 | 现货 | ||
5 mg | ¥ 755 | 现货 | ||
10 mg | ¥ 996 | 现货 | ||
25 mg | ¥ 1,870 | 现货 | ||
50 mg | ¥ 3,320 | 现货 | ||
100 mg | ¥ 4,880 | 现货 | ||
500 mg | ¥ 9,870 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 798 | 现货 |
产品描述 | FLLL32 is an effective JAK2/STAT3 inhibitor (IC50 of <5 μM). |
靶点活性 | JAK2:<5 μM |
体外活性 | In MDA-MB-231 breast and PANC-1 pancreatic cancer cells, FLLL32 downregulates STAT3 phosphorylation and DNA-binding activity. In MDA-MB-231 cells, FLLL32 inhibit the formation of colonies and cell invasion. [1] In human multiple myeloma, glioblastoma, liver cancer, and colorectal cancer cell lines, FLLL32 also leads to the inhibition of cell proliferation and the induction of caspase-3 and PARP cleavages. [2] |
体内活性 | In MDA-MB-231 xenografted mice, FLLL32 (50 mg/kg, i.p.) significantly reduces tumor burdens. [1] In mouse xenografts with OS-33 osteosarcoma cells, FLLL32 (50 mg/kg, i.p.) also inhibits tumor growth by targeting STAT3. [3] |
激酶实验 | JAK2 and other human kinase activity assays: JAK2 kinase activity was assessed with the HTScan JAK2 Kinase Assay Kit per manufacturer's protocol. The possible effects of FLLL32 on the other 10 purified human protein kinases were determined by using a Kinase Profiler Assay. |
细胞实验 | Cells are seeded in 96-well plates (3,000 per well) in triplicate and then treated with 0.5 to 5 μM of FLLL31 or FLLL32 or with 0.5 to 30 μM of curcumin for 72 h. MTT (25 μL) is added to each sample and incubated for 3.5 h. Then, 100 μL of N,N-dimethylformamide solubilization solution are added to each well. The absorbance at 450 nm is read the following day. IC50 are determined using Sigma Plot 9.0 software.(Only for Reference) |
分子量 | 464.55 |
分子式 | C28H32O6 |
CAS No. | 1226895-15-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 85 mg/mL (183 mM)
Ethanol: 24 mg/mL (51.7 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 2.1526 mL | 10.7631 mL | 21.5262 mL | 53.8155 mL |
5 mM | 0.4305 mL | 2.1526 mL | 4.3052 mL | 10.7631 mL | |
10 mM | 0.2153 mL | 1.0763 mL | 2.1526 mL | 5.3816 mL | |
20 mM | 0.1076 mL | 0.5382 mL | 1.0763 mL | 2.6908 mL | |
50 mM | 0.0431 mL | 0.2153 mL | 0.4305 mL | 1.0763 mL | |
DMSO | 100 mM | 0.0215 mL | 0.1076 mL | 0.2153 mL | 0.5382 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
FLLL32 1226895-15-3 Angiogenesis Apoptosis Chromatin/Epigenetic JAK/STAT signaling Stem Cells JAK STAT FLLL 32 inhibit FLLL-32 Inhibitor Janus kinase inhibitor